All News & Press

10.26.2021

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study using Kernel Flow Technology

Read more >

10.19.2021

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

Read more >

10.12.2021

Cybin Files an International Patent Application Covering Psychedelic Delivery Methods

Read more >

10.7.2021

Cybin Announces Additional Adelia Milestone Achievements

Read more >

10.1.2021

Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development

Read more >

9.27.2021

Cybin to Present at Upcoming Cantor and Benzinga Investor Conferences

Read more >

8.19.2021

Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs

Read more >

8.17.2021

Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and Receives a Favorable Patent Claim Opinion

Read more >

8.16.2021

Cybin Announces Election of Theresa Firestone as Director, Results of Shareholders’ Meeting and Adoption of Shareholder Rights Plan

Read more >

8.13.2021

Cybin Inc. Announces 2021 First Quarter Financial Results and Business Highlights

Read more >

8.12.2021

Cybin Announces Additional Adelia Milestone Achievements

Read more >

8.9.2021

Cybin to Present at Canaccord Genuity’s 41st Annual Growth Conference on August 10th

Read more >

8.4.2021

Cybin to Commence Trading on the NYSE American on August 5

Read more >

7.28.2021

Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5

Read more >

7.28.2021

Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares

Read more >

7.27.2021

Cybin Announces Overnight Marketed Public Offering of Common Shares

Read more >

7.21.2021

Cybin Announces Conditional Listing Approval from NYSE American

Read more >

7.13.2021

Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy

Read more >

7.9.2021

Cybin to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13th

Read more >

7.8.2021

Cybin Expands to Europe and Provides Update on Intellectual Property Portfolio

Read more >

7.6.2021

Cybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental Health Centers of Excellence

Read more >

6.28.2021

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

Read more >

6.28.2021

Cybin Inc. Releases Annual Financials and Provides Business Highlights

Read more >

6.25.2021

Cybin to Participate in Grizzle Psychedelics Con on June 28th

Read more >

6.24.2021

Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board

Read more >

6.22.2021

Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study

Read more >

6.18.2021

Cybin to Present at the Emerging Growth Conference on June 23rd

Read more >

6.16.2021

Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

Read more >

6.11.2021

Cybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th

Read more >

6.8.2021

Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy

Read more >

6.2.2021

Cybin to Present at the 2021 LD Micro Invitational XI on June 10, 2021

Read more >

6.1.2021

Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics

Read more >

5.28.2021

Cybin to Present at the Jefferies Virtual Healthcare Conference 2021

Read more >

5.26.2021

Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions

Read more >

5.20.2021

Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Read more >

5.18.2021

Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder

Read more >

5.6.2021

Cybin to Present at the Benzinga Global Small Cap Conference

Read more >

4.26.2021

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Read more >

4.21.2021

Cybin Demonstrates Proof of Concept of its Deuterated Tryptamines for the Treatment of Depression and Addiction

Read more >

4.19.2021

Cybin to Present at the Bloom Burton & Co. Healthcare Investor Conference

Read more >

4.19.2021

Cybin Establishes Clinical Advisory Board of Renowned Physicians, Dr. Maurizio Fava, Dr. Lynn Marie Morski and Dr. Anthony Back

Read more >

4.13.2021

Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

Read more >

3.30.2021

Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe

Read more >

3.22.2021

Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Read more >

3.17.2021

Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th Pre-Clinical Study

Read more >

3.16.2021

Cybin to Present at the Oppenheimer 31st Annual Healthcare Conference

Read more >

3.15.2021

Cybin to Present at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference

Read more >

3.10.2021

Cybin to Present at the Stifel GMP Healthcare Conference – Healthcare Psychedelics: Addressing the Global Mental Health Crisis

Read more >

3.9.2021

Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition

Read more >

3.8.2021

Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021

Read more >

3.3.2021

Cybin Inc. Announces Uplisting to OTCQB Venture Market

Read more >

2.16.2021

Cybin Inc. Releases Financial Highlights and Provides Business Update

Read more >

2.4.2021

Cybin Announces Upsize to Previously Announced bought Deal Offering

Read more >

2.3.2021

Cybin Announces Closing of Upsized Bought Deal Offering

Read more >

1.27.2021

Cybin included in First Psychedelic Exchange Traded Fund

Read more >

1.18.2021

Cybin Announces CDN $20 Million bought Deal Offering

Read more >

1.11.2021

Cybin partners with Kernel to Leverage its Neuroimaging Technology

Read more >

1.5.2021

Cybin Provides Update On Patent Filings & Development Of Therapeutics Program

Read more >

12.29.2020

Cybin Announces First Quarter Financial Results of Clarmin Explorations Inc.

Read more >

12.14.2020

Cybin closes Aquisition of Adelia Therapeutics and Grows IP Portfolio to 7 Patent Filings

Read more >

12.7.2020

Cybin Signs Definitive Agreement To Acquire Adelia Therapeutics As Part Of Its Commitment To Strategic Growth

Read more >

11.10.2020

Cybin Goes Public On NEO Exchange

Read more >

11.5.2020

Cybin Completes Reverse Take-Over Transaction

Read more >

9.1.2020

Cybin Corp Announces Doug Drysdale as Chief Executive Officer

Read more >

8.7.2020

Cybin Applauds TheraPsil’s Advocacy to Bring Psilocybin Therapy to Palliative Care of Canadian Patients

Read more >

7.21.2020

Cybin Corp. Announces Proposed Management Team and Board of Directors of the Resulting Issuer

Read more >

7.7.2020

Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film

Read more >

6.29.2020

Cybin Corp. Announces Reverse Take-Over Transaction and the Engagement of Stifel GMP and Eight ...

Read more >

2.12.2020

Cybin Corp Announces Partnership with the Toronto Centre for Psychedelic Science

Read more >

Cybin Announces Additional Adelia Milestone Achievements

Read more >

Cybin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th

Read more >
2.1.2021

More Psychedelic Companies are going Public

Read more >
1.25.2021

Horizons CEO Steve Hawkins on Launching the First Psychedelic Stock ETF (PSYK)

Read more >
1.17.2021

Cybin, Bryan Johnson and the Greatest Impact on the Future

Read more >
1.12.2021

The Emerging Revival of Psychedelics in Neuroscience

Read more >
1.10.2021

As the Focus on Psychedelic Stocks Increases, So Do the Valuations

Read more >
1.7.2021

5 Groovy Psychedelic Stocks to Buy

Read more >
12.27.2020

2020 was the Year of Psychedelics, Here's why

Read more >
10.24.2020

Psyched: Cybin Raises CA$45M, Numinus Harvests Legal Mushrooms, Toadstool Enters Psychedelic Space

Read more >
close

Our site uses cookies. Learn more about our privacy policy.

I accept the use of cookies